Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 
Search Results



Your search returned 1870 record(s).

Page 21 of 187  |  Previous Page   |  Next Page

Cancer Type:   Sort By:

This Search was Made Possible by:


  Survival: Patients: Toxicity: Treatment: Hospital: Country: Date:
201 26.0 months Metastatic breast cancer 4 Chemotherapy
Regina Elena Institute for Cancer Research Italy 6/2002
Treatment Details: Patients: This Phase II study involved 97 patients with metastatic breast cancer. Treatment: The treatment consisted of the drugs epirubicin and vinorelbine (navelbine). Toxicity: Gra
 
202 26.0 months advanced ovarian cancer 4 Chemotherapy
Dharamshila Cancer Hospital India 7/2005
Treatment Details: Patients: This Phase II study involved 45 women with advanced epithelial ovarian cancer (stage III or IV). The median age was 52. Metastatic sites included liver, pleura, and spleen. Tr
 
203 26.0 months Colorectal cancer with unresectable liver metastases 4 Biologic therapy
Chemotherapy
Mayo Clinic and Foundation United States 12/2005
Treatment Details: Patients: This Phase II study involved 42 patients with colorectal cancer with unresectable liver metastases. Twenty-four patients were men and eighteen were women. Eight patients had chem
 
204 26.0 months Colorectal cancer with unresectable liver metastases 4 Biologic therapy
Chemotherapy
Mayo Clinic and Foundation United States 12/2005
Treatment Details: Patients: This Phase II study involved 42 patients with colorectal cancer with unresectable liver metastases. Twenty-four patients were men and eighteen were women. Eight patients had chem
 
205 25.9 months Metastatic hormone-refractory prostate cancer 4 Immunotherapy
UCSF Comprehensive Cancer Center United States 7/2006
Treatment Details: Patients: This phase III trial involved 127 men with with metastatic, asymptomatic hormone refractory prostate cancer. There were two treatment groups: immunotherapy and placebo. The immun
 
206 25.9 months Platinum-sensitive epithelial ovarian cancer 4 Biologic therapy
Seidman Cancer Center United States 3/2014
Treatment Details: Patients: This phase 2 study involved women with recurrent platinum-sensitive epithelial ovarian, peritoneal, or fallopian tube cancer who were divided into two separate treatment groups.
 
207 25.9 months Metastatic Colorectal Cancer 4 Chemotherapy
Shizuoka Cancer Center Japan 1/2015
Treatment Details: Patients: This phase 2 study involved metastatic colorectal cancer patients who had not received prior chemotherapy. Patients were divided into two separate treatment groups. Group A had 5
 
208 25.7 months Recurrent epithelial ovarian cancer, fallopian tube or primary peritoneal cancer 5 Biologic therapy
Chemotherapy
Washington University School of Medicine United States 12/2013
Treatment Details: Patients: This phase 2 study involved 34 patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancers who had received prior chemotherapy. The average patient
 
209 25.7 months metastatic breast cancer 4 Chemotherapy
Centre F. Baclesse France 11/2005
Treatment Details: Patients: This Phase II study involved 40 women with metastatic breast cancer. The median age was 61.5 years. Metastatic sites included viscera, lung, and liver. None of the patients had
 
210 25.6 months Platinum-sensitive epithelial ovarian cancer 3 Biologic therapy
Seidman Cancer Center United States 3/2014
Treatment Details: Patients: This phase 2 study involved women with recurrent platinum-sensitive epithelial ovarian, peritoneal, or fallopian tube cancer who were divided into two separate treatment groups.
 
Page 21 of 187  | Previous Page  | Next Page